Francis Paul Worden MD

Oncology•Ann Arbor, MI

Endocrine Cancer, Head & Neck Cancer, Hematologic Oncology

Assistant Clinical Professor of Medicine, University Mich Medical School

Join to View Full Profile

1500 East Medical Center DrB1 floor Cancer CTR Recp CAnn Arbor, MI 48109
Phone+1 734-647-8902

Summary

I am a medical oncologist at the University of Michigan. I specialize in the treatment of head and neck cancers and endocrine malignancies and conduct clinical trials related to these disease entities.

Education & Training

University of MichiganFellowship, Hematology and Medical Oncology, 1997 - 2000
Detroit Medical Center/Wayne State UniversityResidency, Internal Medicine/Pediatrics, 1993 - 1997
Indiana University School of MedicineClass of 1993

Certifications & Licensure

MI State Medical License 1997 - 2025
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors for Cancer Castle Connolly, 2005-2014
America's Top Doctors Castle Connolly, 2009-2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma Start of enrollment: 2004 Feb 01
Terminated
Phase 2
A Study of a New Combination and Schedule of Chemotherapy Drugs for the Treatment of Head and Neck Cancer Start of enrollment: 2002 Nov 01
Completed
Phase 2
Treatment for Patients With Metastatic Thyroid Cancer Start of enrollment: 2005 Jul 01
Completed
Phase 2
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
ACTIVE_NOT_RECRUITING
PHASE3
Everolimus Versus Placebo in Head and Neck Cancer Start of enrollment: 2010 Apr 01
Terminated
Phase 2
Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer Start of enrollment: 2010 Sep 09
Completed
Phase 1, Phase 2
A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head and Neck Start of enrollment: 2010 Jun 01
Terminated
Phase 2
Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer Start of enrollment: 2012 Jan 01
Completed
Phase 2
Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery Start of enrollment: 2012 Aug 20
Completed
Phase 2
A Phase II Trial of Proton Pump Inhibitors With Chemotherapy in Patients With Metastatic Head and Neck Cancer Start of enrollment: 2013 Dec 01
Withdrawn
Phase 2
A Randomized Comparative Study of a Weekly Versus Every Other Week Nurse Practitioner-led Symptom Management Clinic for Head and Neck Cancer Patients Undergoing Concurrent Chemotherapy and Radiation Start of enrollment: 2014 Mar 01
Withdrawn
Not Applicable
Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) Start of enrollment: 2014 May 29
Completed
Phase 3
A Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous Cell Carcinoma
Withdrawn
Phase 2
Expansion Trial for Axitinib In Head And Neck Cancer Start of enrollment: 2016 Aug 30
Completed
Phase 2
Phase II Treatment Stratification Trial Using Neck Dissection-Driven Selection to Improve Quality of Life for Low Risk Patients With HPV+ Oropharyngeal Squamous Cell Cancer Start of enrollment: 2016 Oct 31
Completed
Phase 2
Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) Start of enrollment: 2018 Feb 07
COMPLETED
PHASE2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer Start of enrollment: 2017 Apr 27
RECRUITING
PHASE2
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence Start of enrollment: 2018 Aug 20
RECRUITING
PHASE3
Roles: Principal Investigator, Contact
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer Start of enrollment: 2021 Feb 26
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

NCCN Guidelines® Insights: Head and Neck Cancers, Version 2.2025.
A Dimitrios Colevas, Anthony J Cmelak, David G Pfister, Sharon Spencer, Douglas Adkins
Journal of the National Comprehensive Cancer Network. 2025-02-01
Long-Term Outcomes of Neoadjuvant IntraArterial Chemotherapy for Locally Invasive Lacrimal Gland Carcinoma ex Pleomorphic Adenoma.
Lena Juratli, Jane Kim, Sarinee Juntipwong, Victor M Elner, Scott McLean
Ophthalmic Plastic and Reconstructive Surgery. 2024-12-24
Squamoid Eccrine Ductal Carcinoma Displays Ultraviolet Mutations and Intermediate Gene Expression Relative to Squamous Cell Carcinoma, Microcystic Adnexal Carcinoma, a...
Paul W Harms, Mason Runge, May P Chan, Chia-Jen Liu, Zhaoping Qin
Modern Pathology. 2024-11-01

Journal Articles

Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors
Erin F Cobain, Francis Worden, Scott M Schuetze, Mark M Zalupski, Vaibhav Sahai, Ajjai Alva, Anne F Schott, Moshe Talpaz, JAMA Oncology
Efficacy of Selpercatinib in RET-Altered Thyroid Cancers
Lori J Wirth, Jochen Lorch, Francis Worden, Marcia Brose, Taofeek K Owonikoko, Mark E Burkard, Todd M Bauer, Viola W Zhu, Nehal Lakhani, Victor Moreno, Manisha H Shah, New England Journal of Medicine

Lectures

Head and Neck Cancer
ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019
Updates on Current Programs and Resources
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Other

Postoperative radiation therapy in the management of head and neck cancer
Worden FP, Eisbruch A, Jolly S
http://www.uptodate.com/contents/postoperative-radiation-therapy-in-the-management-of-head-and-neck-
UpToDate, Wolters Kluwer Health - 2012-02-27
Treatment of early (stage I and II) head and neck cancer: The oropharynx
Worden FP, Eisbruch A, Bradford CR
http://www.uptodate.com/contents/treatment-of-early-stage-i-and-ii-head-and-neck-cancer-the-orophary
UpToDate, Wolters Kluwer Health - 2012-10-31
Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The oropharynx
Worden FP, Eisbruch A, Bradford CR
http://www.uptodate.com/contents/treatment-of-locoregionally-advanced-stage-iii-and-iv-head-and-neck
UpToDate, Wolters Kluwer Health - 2012-06-05

Authored Content

Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020
Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020
Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020

Press Mentions

Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual MeetingMarch 25th, 2025
Preview of the 93rd American Thyroid Association Annual MeetingJuly 1st, 2024
Axitinib Improves Survival for Patients with Incurable Head and Neck CancerOctober 20th, 2020
Join now to see all